Pulse Biosciences surpasses enrollment midpoint in NANOPULSE-AF pivotal study

PULSE BIOSCIENCES, INC.

Study commenced April 2026; already past midpoint, enrolling at up to 30 sites including outside U.S.
CMO David Kenigsberg cites strong enrollment trajectory reflecting investigator enthusiasm for nPulse technology.
Top-enrolling investigator Frank Cuoco notes minimal learning curve and seamless workflow integration.
Company to provide further commentary on study progress during August 6, 2026 earnings call.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.